Acute Myeloid Leukemia research hub

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

This study is looking at a medicine called ponatinib for children aged 1 to 17 with certain types of cancer, like leukemia and lymphoma. We want to see how safe it is and how well it works when other treatments haven't helped or aren't suitable.

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses